title: Pathological complete response in advanced gastric stromal tumor after imatinib mesylate therapy: a case report.
abstract: BACKGROUND
  Gastrointestinal stromal tumors are a rare neoplasm exhibiting, in most cases, mutations of c-kit. Imatinib mesylate is the standard treatment for patients who have advanced gastrointestinal stromal tumors. Although the response rate in patients treated with imatinib mesylate in prospective clinical studies is above 50%, a complete response is very rare. We report the case of a patient with a gastric gastrointestinal stromal tumor who had a pathological complete response after neoadjuvant treatment with imatinib mesylate.
  
  
  METHODS
  We report the case of a 54-year-old Arab woman with a gastrointestinal stromal tumor who had a pathological complete response after neoadjuvant treatment with imatinib mesylate.
  
  
  CONCLUSIONS
  The pathological examination of our patient documented a complete pathological response after imatinib therapy. Recently, it has been confirmed that the kinase genotype of KIT and platelet-derived growth factor receptor α can accurately predict a good response to imatinib mesylate therapy. We propose that this patient had a mutation conferring high sensitivity to imatinib mesylate.
authors: Medical Oncology Department, Hassan II University Hospital, Fez, Morocco. elmesbahiomar@yahoo.fr.
authors: Omar
authors: O
authors: El Mesbahi
authors: Sami Aziz
authors: SA
authors: Brahmi
authors: Yousra
authors: Y
authors: Akasbi
authors: Fatima Zahra
authors: FZ
authors: El Mrabet
authors: Anas
authors: A
authors: Touyar
authors: Abdelmalek
authors: A
authors: Ossaden
authors: Kaoutar
authors: K
authors: Znati
authors: Khalid
authors: K
authors: Maazaz
authors: Affaf
authors: A
authors: Amarti
authors: Siham
authors: S
authors: Tizniti
authors: Khalid Ait
authors: KA
authors: Taleb
authors: Adil
authors: A
authors: Ibrahimi
references: Eur J Gastroenterol Hepatol. 2007 Aug;19(8):711-3
references: 17625442
references: Ann Oncol. 2010 May;21 Suppl 5:v98-102
references: 20555113
references: J Clin Oncol. 2006 Oct 10;24(29):4764-74
references: 16954519
references: J Clin Oncol. 2009 Jul 1;27(19):3141-7
references: 19451435
references: Eur J Surg Oncol. 2009 Jul;35(7):739-45
references: 19110398
references: N Engl J Med. 2002 Aug 15;347(7):472-80
references: 12181401
references: World J Gastroenterol. 2008 Jun 21;14(23):3763-7
references: 18595147